BridgeBio Pharma Secures $1.25B For New Drug Launch
Public biopharmaceutical company BridgeBio Pharma announced Thursday that it has raised up to $1.25 billion in capital from Blue Owl Capital and the Canada Pension Plan Investment Board to accelerate the...To view the full article, register now.
Already a subscriber? Click here to view full article